KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Short term Debt (2017 - 2025)

Astrana Health's Short term Debt history spans 13 years, with the latest figure at $47.9 million for Q3 2025.

  • For Q3 2025, Short term Debt rose 219.1% year-over-year to $47.9 million; the TTM value through Sep 2025 reached $47.9 million, up 219.1%, while the annual FY2024 figure was $9.4 million, 51.92% down from the prior year.
  • Short term Debt for Q3 2025 was $47.9 million at Astrana Health, up from $12.5 million in the prior quarter.
  • Across five years, Short term Debt topped out at $47.9 million in Q3 2025 and bottomed at $205000.0 in Q2 2021.
  • The 5-year median for Short term Debt is $3.1 million (2022), against an average of $9.4 million.
  • The largest annual shift saw Short term Debt tumbled 97.84% in 2021 before it soared 3241.38% in 2024.
  • A 5-year view of Short term Debt shows it stood at $780000.0 in 2021, then dropped by 20.64% to $619000.0 in 2022, then surged by 3050.24% to $19.5 million in 2023, then crashed by 51.92% to $9.4 million in 2024, then soared by 410.56% to $47.9 million in 2025.
  • Per Business Quant, the three most recent readings for ASTH's Short term Debt are $47.9 million (Q3 2025), $12.5 million (Q2 2025), and $9.4 million (Q4 2024).